Combined approaches for HIV cure
Year: 2013
Type: review
Abstract: PURPOSE OF REVIEW: A serious effort has begun to develop therapies that may be capable of eradicating established HIV infection in man. Because of the biological complexity of HIV infection that persists despite potent antiretroviral therapy, it is widely believed that if such therapies can be developed they will involve complex, multimodality approaches. We highlight some of the recent studies in this effort. RECENT FINDINGS: An inhibitor of histone deacetylase has been demonstrated to disrupt latency in man, and new histone deacetylase inhibitors have been identified. Other potential targets, such as histone methyltransferase, protein kinase C, and BRD4, have been recently studied. Model systems, both in primary cells and in animal models, are beginning to be validated. In the clinic, immune-based therapies to aid in the clearance of persistent infection are also being tested. SUMMARY: It is too early to know what combination eradication therapies for HIV infection will look like in the future, but candidate therapies and model systems to perform preclinical validation are beginning to take shape.
Source: Current Opinion in HIV and AIDS
Authors: David M. Margolis, Daria J. Hazuda
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Funders: Georgia Clinical and Translational Science Alliance, National Institutes of Health, U.S. Public Health Service, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Allergy and Infectious Diseases, National Center for Research Resources, Center for AIDS Research, University of North Carolina at Chapel Hill
Awards: G1939027404, G2307004170, Innovative therapies to elimate persistent HIV Infection, Nanocrystal delivery to the CNS to improve HIV therapy, UNC Clinical and Translational Science Award, G68625873, G7477205992, G7817696117, The University of North Carolina Center for AIDS Research, HIV Latency, Epigenetics, and Therapeutics
OpenAlex ID: W2024296689